Biomarker-guided treatment for patients with colon cancer is needed. We tested ABCG2 and topoisomerase 1 (TOP1) mRNA expression as predictive biomarkers for irinotecan benefit in the PETACC-3 patient cohort. The present study included 580 patients with mRNA expression data from Stage III colon cancer samples from the PETACC-3 study, which randomized the patients to Fluorouracil/leucovorin (5FUL) +/- irinotecan. The primary end-points were recurrence free survival (RFS) and overall survival (OS). Patients were divided into one group with high ABCG2 expression (above median) and low TOP-1 expression (below 75 percentile) ("resistant") (n = 216) and another group including all other combinations of these two genes ("sensitive") (n = 364). The rationale for the cut-offs were based on the distribution of expression levels in the PETACC-3 Stage II set of patients, where ABCG2 was unimodal and TOP1 was bimodal with a high expression level mode in the top quarter of the patients. Cox proportional hazards regression was used to estimate the hazard ratios and the association between variables and end-points and log-rank tests to assess the statistical significance of differences in survival between groups. Kaplan-Meier estimates of the survival functions were used for visualization and estimation of survival rates at specific time points. Significant differences were found for both RFS (Hazard ratio (HR): 0.63 (0.44-0.92); p = 0.016) and OS (HR: 0.60 (0.39-0.93); p = 0.02) between the two biomarker groups when the patients received FOLFIRI (5FUL+irinotecan). Considering only the Microsatellite Stable (MSS) and Microsatellite Instability-Low (MSI-L) patients (n = 470), the differences were even more pronounced. In contrast, no significant differences were observed between the groups when patients received 5FUL alone. This study shows that the combination of ABCG2 and TOP1 gene expression significantly divided the Stage III colon cancer patients into two groups regarding benefit from adjuvant treatment with FOLFIRI but not 5FUL.

Digestive Oncology Department University Hospitals Leuven and KU Leuven 3001 Leuven Belgium

RECETOX Faculty of Science Masarykova Univerzita 625 00 Brno Czech Republic

Scandion Oncology Symbion 2100 Copenhagen Denmark

Section of Molecular Disease Biology Institute of Drug Design and Pharmacology Faculty of Health and Medical Sciences University of Copenhagen 2100 Copenhagen Denmark

University Institute of Pathology University of Lausanne 1011 Lausanne Switzerland

Zobrazit více v PubMed

André T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., Bonetti A., Clingan P., Bridgewater J., Rivera F., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 2009;27:3109–3116. doi: 10.1200/JCO.2008.20.6771. PubMed DOI

Tournigand C., André T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol. 2004;22:229–237. doi: 10.1200/JCO.2004.05.113. PubMed DOI

Van Cutsem E., Labianca R., Bodoky G., Barone C., Aranda E., Nordlinger B., Topham C., Tabernero J., André T., Sobrero A.F., et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 2009;27:3117–3125. doi: 10.1200/JCO.2008.21.6663. PubMed DOI

Saltz L.B., Niedzwiecki D., Hollis D., Goldberg R.M., Hantel A., Thomas J.P., Fields A.L., Mayer R.J. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J. Clin. Oncol. 2007;25:3456–3461. doi: 10.1200/JCO.2007.11.2144. PubMed DOI

Jensen N.F., Stenvang J., Beck M.K., Hanáková B., Belling K.C., Do K.N., Viuff B., Nygård S.B., Gupta R., Rasmussen M.H., et al. Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Mol. Oncol. 2015;9:1169–1185. doi: 10.1016/j.molonc.2015.02.008. PubMed DOI PMC

Jandu H., Aluzaite K., Fogh L., Thrane S.W., Noer J.B., Proszek J., Do K.N., Hansen S.N., Damsgaard B., Nielsen S.L., et al. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer. 2016;16:34. doi: 10.1186/s12885-016-2071-1. PubMed DOI PMC

Nygård S.B., Vainer B., Nielsen S.L., Bosman F., Tejpar S., Roth A., Delorenzi M., Brünner N., Budinska E. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer. Clin. Cancer Res. 2016;22:1621–1631. doi: 10.1158/1078-0432.CCR-15-0561. PubMed DOI

Popovici V., Budinska E., Tejpar S., Weinrich S., Estrella H., Hodgson G., Van Cutsem E., Xie T., Bosman F.T., Roth A.D., et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 2012;30:1288–1295. doi: 10.1200/JCO.2011.39.5814. PubMed DOI

Tibshirani R. The lasso method for variable selection in the Cox model. Stat. Med. 1997;16:385–395. doi: 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3. PubMed DOI

Klingbiel D., Saridaki Z., Roth A.D., Bosman F.T., Delorenzi M., Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: Results of the PETACC-3 trial. Ann. Oncol. 2015;26:126–132. doi: 10.1093/annonc/mdu499. PubMed DOI

Nielsen D.L., Palshof J.A., Brunner N., Stenvang J., Viuff B.M. Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review. Int. J. Mol. Sci. 2017;18:1926. doi: 10.3390/ijms18091926. PubMed DOI PMC

Ambjørner S.E., Wiese M., Köhler S.C., Svindt J., Lund X.L., Gajhede M., Saaby L., Brodin B., Rump S., Weigt H., et al. The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP. Cells. 2020;9:613. doi: 10.3390/cells9030613. PubMed DOI PMC

Stenvang J., Lima T., Nielsen S.L., Drejer J., Brunner N., Christophersen P. The volume regulated anion channel inhibitor NS3728 to enhance the cytotoxic effects of SN-38 in human colorectal cancer cells grown in vitro. J. Clin. Oncol. 2016;34:e23170. doi: 10.1200/JCO.2016.34.15_suppl.e23170. DOI

Cederbye C.N., Palshof J.A., Hansen T.P., Duun-Henriksen A.K., Linnemann D., Stenvang J., Nielsen D.L., Brünner N., Viuff B.M. Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue. Sci. Rep. 2016;6:26997. doi: 10.1038/srep26997. PubMed DOI PMC

Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 2009;101:1446–1452. doi: 10.1093/jnci/djp335. PubMed DOI PMC

Budinska E., Popovici V., Tejpar S., D’Ario G., Lapique N., Sikora K.O., Di Narzo A.F., Yan P., Hodgson J.G., Weinrich S., et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 2013;231:63–76. doi: 10.1002/path.4212. PubMed DOI PMC

R Core Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2017.

Sønderstrup I.M., Nygård S.B., Poulsen T.S., Linnemann D., Stenvang J., Nielsen H.J., Bartek J., Brünner N., Nørgaard P., Riis L. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers. Mol. Oncol. 2015;9:1207–1217. doi: 10.1016/j.molonc.2015.02.009. PubMed DOI PMC

McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK) J. Natl. Cancer Inst. 2005;97:1180–1184. doi: 10.1093/jnci/dji237. PubMed DOI

Using empirical biological knowledge to infer regulatory networks from multi-omics data